You are here

Home » Content

Yetişkin Düşük Dereceli Gliomlarda Sağkalım ve Prognostik Faktörler

Survival and Prognostic Factors in Adult Low-Grade Gliomas

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2016
DOI: 
10.5505/abantmedj.2016.19327

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
INTRODUCTION: The purpose of this study was to evaluate survival in patients with nonpilocytic low-grade gliomas (LGGs). METHODS: Records of 70 adult patients with LGGs diagnosed between 2003 and 2007 at Dr Abdurrahman Yurtarslan Oncology, Education and Research Hospital (AOH), Ankara, Turkey, were retrospectively reviewed. The Kaplan-Meier method estimated overall survival (OS). RESULTS: Median age at diagnosis was 37.5 years (range; 20- 73) with a slightly higher male predominance (male / female: 1.26). Median follow-up was 39 (range, 4-79) months. Operative pathology revealed pure astrocytoma in 54% oligodendroglioma in 21%, and oligoastrocytoma in 10% of patients. Subtotal resection (STR) was achieved in 44 patients (63%), gross total resection (GTR) in 19 (27%), and biopsy only in 7 (10%). Presenting symptoms in order of frequency were headache, seizure and motor disturbances. Median time interval between surgery and radiotherapy was 7 weeks ranging from 3 to 78. Median OS was 71 months (range, 4-80 months). DISCUSSION AND CONCLUSION: Survival was not significantly influenced by age, gender, extent of resection, tumor size, histology and time interval between surgery and radiotherapy. Statistically significant good prognostic factors for OS was Karnofsky Performance Status (KPS) > 70 (p < 0.001).
Bookmark/Search this post with
Abstract (Original Language): 
GİRİŞ ve AMAÇ: Pilositik olmayan düşük dereceli gliomlarda sağkalım değerlendirmek. YÖNTEM ve GEREÇLER: 2003-2007 yılları arasında Ankara Onkoloji Eğitim ve Araştırma Hastanesinde (AOH) Düşük Dereceli Glial Tümör tanısıyla tedavi edilen 70 erişkin hasta geriye dönük olarak incelendi. Genel Sağkalım (GSK) tahminleri Kaplan Meier ile yapıldı. BULGULAR: Ortanca yaş 37.5 (aralık; 20-73) ve erkek çoğunlukdaydı (erkek/kadın: 1.26). Ortanca takip süresi 39 aydı (aralık; 4-79). Cerrahi sonucu hastaların %54'ünün saf astrositom, %21'inin oligodendrogliom, %10'unun ise oligoastrositom olduğu belirlendi. Hastaların 44'üne (%63) subtotal rezeksiyon (STR), 19'una (%27) gross total rezeksiyon (GTR) ve 7'sine (%10) biopsi uygulandı. Başvuru şikayeti sıklık sırasıyla başağrısı, nöbet ve motor bozukluktu. Cerrahi ile radyoterapi arasındaki ortanca süre 7 hafta olup, 3 hafta ile 78 hafta arasında değişmekteydi. Ortanca GSK 71 ay (aralık, 4-80 ay) olarak bulundu. TARTIŞMA ve SONUÇ: Sağkalım; yaş, cinsiyet, tümör boyutu, histolojik tip ve cerrahi sonrası radyoterapi başlama zamanından istatistiki olarak anlamlı derecede etkilenmemiştir. Karnofsky Performans skorunun (KPS) 70'in üstünde olması istatistiksel olarak anlamlı iyi prognostik faktördür (p < 0.001).
FULL TEXT (PDF): 
PDF icon arastirmax-yetiskin-dusuk-dereceli-gliomlarda-sagkalim-prognostik-faktorler.pdf
  • 3
173
180
  • Turkish

REFERENCES

References: 

1. Sherman JH, Weintraub D, Lopes MBS, Schiff
D. Low-Grade Gliomas. In: Norden AD et al
editors. Primary central nervous system
tumors, Pathogenesis and Therapy. New
York: Humane Press, 2011: Part 2, p.173-194.
2. Ruiz J, Lesser GJ. Low-grade gliomas. Curr
Treat Options Oncol. 2009; 10: 231-42.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, et al. The 200 WHO
classification of tumours of the central
nervous system. Acta Neuropathol. 2007;
114: 97–109.
4. Soffietti R, Baumert BG, Bello L, von Deimling
A, Duffau H, Frénay M, et al. European
Federation of Neurological Societies.
Guidelines on management of low-grade
gliomas: report of an EFNS-EANO Task Force.
Eur J Neurol. 2010; 17: 1124-33.
5. Pouratian N, Mut M, Jagannathan J, Lopes
MB, Shaffrey ME, Schiff D. Low-grade gliomas
in older patients: a retrospective analysis of
prognostic factors. J Neurooncol. 2008; 90:
341-50.
6. Sanders WP, Christoforidis GA. Imaging of
low-grade primary brain tumors. In: Rock JP
et al editors. The practical management of
low grade primary brain tumors.
Philadelphia: Lippincott Williams & Wilkins,
1999: p.5-32.
7. Schomas DA, Laack NN, Rao RD, Meyer FB,
Shaw EG, O'Neill BP et al. Intracranial lowgrade
gliomas in adults: 30-year experience
with long-term follow-up at Mayo Clinic.
Neuro Oncol. 2009; 11: 437-45.
8. Karim AB, Maat B, Hatlevoll R, Menten J,
Rutten EH, Thomas DG et al. A randomized
trial on dose-response in radiation therapy of
low-grade cerebral glioma. Int J Radiat Oncol
Biol Phys. 1996; 36: 549-56.
9. van den Bent MJ, Afra D, de Witte O, Ben
Hassel M, Schraub S, Hoang-Xuan K et al.
Long-term efficacy of early versus delayed
radiotherapy for low-grade astrocytoma and
oligodendroglioma in adults. Lancet. 2005;
366: 985-90. Erratum in: Lancet. 2006; 367:
1818.
10. Shaw E, Arusell R, Scheithauer B, O'Fallon J,
O'Neill B, Dinapoli R, et al Prospective
randomized trial of low- versus high-dose
radiation therapy in adults with
supratentorial low-grade glioma. J Clin Oncol.
2002; 20: 2267-76.
11. Lote K, Egeland T, Hager B, Stenwig B,
Skullerud K, Berg-Johnsen J et al. Survival,
prognostic factors, and therapeutic efficacy
in low-grade glioma: a retrospective study in
379 patients. J Clin Oncol. 1997; 15: 3129-40.
12. Shaw EG, Scheithauer BW, O’Fallon JR.
Supratentorial gliomas: a comparative study
by grade and histologic type. J Neurooncol.
1997; 31: 273–8.
13. Eyre HJ, Crowley JJ, Townsend JJ, Eltringham
JR, Morantz RA, Schulman SF et al. A
randomized trial of radiotherapy versus
radiotherapy plus CCNU for incompletely
resected low-grade gliomas: a Southwest
Oncology Group study. J Neurosurg. 1993:
78: 909–14.
14. Quinn JA, Reardon DA, Friedman AH, Rich JN,
Sampson JH, Provenzale JM, et al. Phase II
trial of temozolomide in patients with
progressive low-grade glioma. J Clin Oncol.
2003; 21: 646–51.
15. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV
chemotherapy for recurrent
oligodendrogliomas and oligoastrocytomas.
Neurosurgery. 1998; 43: 1066–73.
16. van den Bent MJ, Kros JM, Heimans JJ, Pronk
LC, van Groeningen CJ, Krouwer HG, et al.
Response rate and prognostic factors of
recurrent oligodendroglioma treated with
procarbazine, CCNU, and vincristine
chemotherapy. Neurology. 1998; 51: 1140–5.
Arslan S ve ark.
Abant Med J 2016;5(3):173-180 180
17. van den Bent MJ, Taphoorn MJ, Brandes AA,
Menten J, Stupp R, Frenay M, et al. Phase II
study of first-line chemotherapy with
temozolomide in recurrent oligodendroglial
tumors: the European Organization for
Research and Treatment of Cancer Brain
Tumor Group Study 26971. J Clin Oncol.
2003; 21: 2525–8.
18. Claus EB, Black PM. Survival rates and
patterns of care for patients diagnosed with
supratentorial low-grade gliomas: data from
the SEER program, 1973–2001. Cancer 2006;
106: 1358–63.
19. Bauman G, Pahapill P, Macdonald D, Fisher B,
Leighton C, Cairncross G. Low grade glioma:
A measuring radiographic response to
radiotherapy. Can J Neurol Sci. 1999; 26: 18–
22.
20. Bauman G, Fisher B, Watling C, Cairncross JG,
Macdonald D. Adult supratentorial low-grade
glioma: long-term experience at a single
institution. Int J Radiat Oncol Biol Phys. 2009;
75: 1401-7.
21. Claus EB, Horlacher A, Hsu L, Schwartz RB,
Dello-lacono D, Talos F, Jolesz FA, Black PM.
Survival rates in patients with low-grade
glioma after intraoperative magnetic
resonance image guidance. Cancer. 2005;
103: 1227–33.
22. Bello L, Gallucci M, Fava M, Carrabba G,
Giussani C, Acerbi F, Baratta P, Songa V,
Conte V, Branca V, Stocchetti N, Papagno C,
Gaini SM. Intraoperative subcortical
language tract mapping guides surgical
removal of gliomas involving speech areas.
Neurosurgery. 2007; 60: 67–80
23. Smith JS, Chang EF, Lamborn KR, Chang SM,
Prados MD, Cha S, Tihan T, Vandenberg S,
McDermott MW, Berger MS. Role of extent
of resection in the long-term outcome of lowgrade
hemispheric gliomas. J Clin Oncol.
2008; 26: 1338–45.
24. Duffau H. Surgery of low-grade gliomas:
towards a functional neurooncology. Curr
Opin Oncol. 2009; 21: 543–9.
25. Janny P, Cure H, Mohr M, Heldt N,
Kwiatkowski F, Lemaire JJ, et al. Low grade
supratentorial astrocytomas: management
and prognostic factors. Cancer. 1994; 73:
1937–45.
26. Leighton C, Fisher B, Bauman G, Depiero S,
Stitt L, MacDonald D, et al. Supratentorial
low-grade glioma in adults: an analysis of
prognostic factors and timing of radiation. J
Clin Oncol. 1997; 15: 1294–301.
27. Van Veelen ML, Avezaat CJ, Kros JM, van
Putten W, Vecht C. Supratentorial low grade
astrocytoma: prognostic factors,
dedifferentiation, and the issue of early
versus late surgery. J Neurol Neurosurg
Psychiatry. 1998; 64: 581–7.
28. Grabenbauer GG, Roedel CM, Paulus W,
Ganslandt O, Schuchardt U, Buchfelder M, et
al. Supratentorial low-grade glioma: results
and prognostic factors following
postoperative radiotherapy. Strahlenther
Onkol. 2000; 176: 259–64.
29. Kiebert GM, Curran D, Aaronson NK, Bolla M,
Menten J, Rutten EH, et al. Quality of life after
radiation therapy of cerebral low-grade
gliomas of the adult: results of a randomised
phase III trial on dose response (EORTC trial
22844). Eur J Cancer. 1998; 34.

Thank you for copying data from http://www.arastirmax.com